21健讯Daily | 黑龙江八部门联合治理“神医”广告乱象；替尔泊肽“头对头”完胜司美格鲁肽

Policy Developments - Heilongjiang Province has initiated a joint action among eight departments to regulate illegal medical advertisements, particularly targeting "miracle doctor" ads that mislead consumers by using false credentials or endorsements [2] Drug and Device Approvals - Merck announced the launch of its new antibiotic, Recarbrio® (Imipenem/Cilastatin/Relebactam), in China, which is indicated for treating infections caused by sensitive Gram-negative bacteria in patients aged 18 and older [4] Capital Markets - Jingtai Holdings plans to acquire 90% of Shanghai Siwei Medical Technology for a total consideration of 250 million yuan, enhancing its capabilities in AI healthcare and drug development [6] - Yihe Jiaye has signed a strategic cooperation framework agreement with Shenzhen Hanyu Pharmaceutical and Shenzhen Hanyu Health Technology to develop a sleep health ecosystem through resource integration [7] Industry Developments - Kintor Pharmaceutical released preliminary clinical data for its CT0596 CAR-T cell injection targeting BCMA, currently under exploration for treating relapsed/refractory multiple myeloma [9] - Hanyu Pharmaceutical has agreed to collaborate with Shenzhen Carbon Cloud Peptide Technology on the development of a novel peptide drug targeting GLP-1R/GIPR/GCGR, which currently has no similar products approved for market [10] - Eli Lilly's tirzepatide has shown superior weight loss efficacy compared to Novo Nordisk's semaglutide in a head-to-head clinical trial, potentially reshaping the obesity treatment market [11]